IP Library Granted Patent US 10,226,458
Granted Patent B2
US 10,226,458 · App. 15/388,554 · Granted Mar 12, 2019

Pharmaceutical compositions comprising sorbitan esters

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,458
App. No.
15/388,554
Granted
Mar 12, 2019
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

Claims (38)

1. A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising:

(a) compound A-7:

(b) sorbitan laurate;

(c) polysorbate 20; and

(d) an aqueous vehicle,

wherein the composition forms an aqueous, flocculated, injectable suspension.

2. The method of claim 1 , wherein depression is treated.

3. The method of claim 1 , wherein bipolar disorder is treated.

4. The method of claim 1 , wherein schizophrenia is treated.

5. The method of claim 1 , wherein the ratio of components (b) to (c) is approximately 5 to 2, by weight.

6. The method of claim 1 , comprising about 0.2- 1 weight percent sorbitan laurate.

7. The method of claim 1 , comprising about 0.4- 0.7 weight percent sorbitan laurate.

8. The method of claim 1 , comprising about 0.5 weight percent sorbitan laurate.

9. The method of claim 1 , comprising about 0.05- 0.8 weight percent polysorbate 20.

10. The method of claim 1 , comprising about 0.1- 0.3 weight percent polysorbate 20.

11. The method of claim 1 , comprising about 0.2 weight percent polysorbate 20.

12. The method of claim 1 , comprising approximately 15- 35 weight percent compound A-7.

13. The method of claim 1 , comprising approximately 20- 30 weight percent compound A-7.

14. A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof comprising administering to the subject an injectable pharmaceutical composition comprising:

(a) 15-35 weight percent compound A-7:

(b) approximately 0.2-1 weight percent sorbitan laurate;

(c) approximately 0.05-0.8 weight percent polysorbate 20; and

(d) an aqueous carrier.

15. The method of claim 14 , wherein schizophrenia is treated.

16. A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof comprising administering to the subject an injectable composition comprising:

(a) compound A-7:

(b) sorbitan laurate;

(c) polysorbate 20; and

(d) an aqueous vehicle.

17. The method of claim 16 , wherein the composition further comprises a buffer.

18. The method of claim 17 , wherein the buffer is a phosphate, citrate, tartrate or acetate buffer.

19. The method of claim 16 , wherein schizophrenia is treated.

20. A method for treating schizophrenia, bipolar disorder, or depression in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising:

(a) 24-30 weight percent compound A-7:

(b) 0.2-1 weight percent sorbitan laurate;

(c) 0.1-0.3 weight percent polysorbate 20; and

(d) an aqueous vehicle.

21. The method of claim 20 , wherein schizophrenia is treated.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER 15/388544 PREVIOUSLY RECORDED ON REEL 041839 FRAME 0819. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 14, 2017
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.; VANDIVER, JENNIFER
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 042253/0654 →
SECURITY INTEREST Recorded Apr 4, 2017
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 041846/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2017
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.; VANDIVER, JENNIFER
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 041839/0819 →